How to investigate levels of Adherence to antiretroviral ... - INRUD
How to investigate levels of Adherence to antiretroviral ... - INRUD
How to investigate levels of Adherence to antiretroviral ... - INRUD
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>How</strong> <strong>to</strong> Investigate <strong>Adherence</strong> <strong>to</strong> Antiretroviral Treatment:<br />
An Indica<strong>to</strong>r-Based Approach<br />
Table 4. Patient care indica<strong>to</strong>rs<br />
1. Patient knowledge <strong>of</strong> ARV regimen—Percentage <strong>of</strong> patients who know when <strong>to</strong> take each <strong>of</strong><br />
their ARV medicines and how much <strong>to</strong> take each time.<br />
2. Patient waiting time—Average amount <strong>of</strong> time patients spend in the facility during a visit.<br />
3. Patient travel time <strong>to</strong> care—Average amount <strong>of</strong> time spent travelling <strong>to</strong> health facility <strong>to</strong><br />
receive care.<br />
4. Patient travel cost <strong>to</strong> care—Average cost for travelling <strong>to</strong> health facility <strong>to</strong> receive care.<br />
Table 5. Demographic indica<strong>to</strong>rs<br />
1. Average age <strong>of</strong> patients.<br />
2. Gender—Percentage <strong>of</strong> patients who are female.<br />
Facility indica<strong>to</strong>rs determinants<br />
ARV availability on day <strong>of</strong> data collection<br />
1. The percentage <strong>of</strong> a selected list <strong>of</strong> first-line adult ARVs currently in s<strong>to</strong>ck.<br />
2. The percentage <strong>of</strong> a selected list <strong>of</strong> first-line paediatric ARVs currently in s<strong>to</strong>ck.<br />
Rationale<br />
Source <strong>of</strong> data<br />
Data collection<br />
Lack <strong>of</strong> availability <strong>of</strong> ARVs can be a key system-related barrier <strong>to</strong> adherence.<br />
Observation in health facility pharmacies on day <strong>of</strong> data collection.<br />
Check which medicines on a list <strong>of</strong> ARVs intended <strong>to</strong> be in s<strong>to</strong>ck are actually<br />
in s<strong>to</strong>ck (any amount will do as long as it is in s<strong>to</strong>ck and in date).<br />
Computation (Number <strong>of</strong> ARVs in s<strong>to</strong>ck/number <strong>of</strong> ARVs intended <strong>to</strong> be in s<strong>to</strong>ck) × 100.<br />
Comments<br />
Before the survey, it is necessary <strong>to</strong> agree a list <strong>of</strong> up <strong>to</strong> 10 key first-line<br />
ARVs for adults and children which should always be in s<strong>to</strong>ck.<br />
Key medicine availability<br />
3. The percentage <strong>of</strong> key medicines for HIV-associated illness currently in s<strong>to</strong>ck.<br />
Rationale<br />
Source <strong>of</strong> data<br />
Data collection<br />
Computation<br />
Comments<br />
Lack <strong>of</strong> availability <strong>of</strong> key medicines needed <strong>to</strong> treat or prevent ARV side<br />
effects, opportunistic infections, or other HIV-associated illnesses can be a<br />
barrier <strong>to</strong> ARV adherence.<br />
Observation in health facility pharmacies on day <strong>of</strong> data collection.<br />
Check which medicines on a tracer list <strong>of</strong> key medicines needed <strong>to</strong> treat or<br />
prevent HIV-associated opportunistic infections and other illness are actually<br />
in s<strong>to</strong>ck (any amount will do as long as it is in s<strong>to</strong>ck and in date).<br />
(Number <strong>of</strong> medicines on tracer list in s<strong>to</strong>ck /number <strong>of</strong> medicines on tracer<br />
list) × 100.<br />
Need <strong>to</strong> prepare tracer list <strong>of</strong> up <strong>to</strong> 10 key medicines.<br />
16
Change language